---
figid: PMC9478252__medi-101-e30270-g007
pmcid: PMC9478252
image_filename: medi-101-e30270-g007.jpg
figure_link: /pmc/articles/PMC9478252/figure/F7/
number: Figure 7
figure_title: ''
caption: Analysis of the relevant role of SLC22A8 in immunotherapy. (A) Differences
  in immunotherapy clinical response scores between high and low SLC22A8 expression
  groups. (B) Differences in cancer-immune cycle step scores between high and low
  SLC22A8 expression groups. (C) Correlation of SLC22A8 with immunotherapy predicted
  pathway enrichment scores. (D) Correlation of SLC22A8 with cancer-immune cycle steps
  in ccRCC. *P < .05, **P < .01, ***P < .001. ccRCC = clear cell renal cell carcinoma.
article_title: 'SLC22A8: An indicator for tumor immune microenvironment and prognosis
  of ccRCC from a comprehensive analysis of bioinformatics.'
citation: Ke Xu, et al. Medicine (Baltimore). 2022 Sep 16;101(37):e30270.
year: '2022'

doi: 10.1097/MD.0000000000030270
journal_title: Medicine
journal_nlm_ta: Medicine (Baltimore)
publisher_name: Lippincott Williams & Wilkins

keywords:
- ccRCC
- DNA methylation
- immune infiltration
- prognostic biomarker
- SLC22A8

---
